[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$apiParty6fBuHLCPZ1LTYs42XHdVbjpSDOYYPYzyxeAGwSN5Tp8":3,"$apiParty4ogYevKFVy9hen0LlfDdftspjgxin0ggeGY6-F4eAL8":563,"$apiParty4ogYevKFVy9hen0LlfDdftspjgxin0ggeGY6-F4eAL8$H93EERW16b":563},{"product_data":4,"scene_data":21,"task_data":407,"modality_data":441,"domain_data":478},[5,9,12,15,18],{"name":6,"value":7,"add_value":8,"describe":8},"Rivo","1","",{"name":10,"value":11,"add_value":8,"describe":8},"Cubo","2",{"name":13,"value":14,"add_value":8,"describe":8},"Moye","3",{"name":16,"value":17,"add_value":8,"describe":8},"Juro","4",{"name":19,"value":20,"add_value":8,"describe":8},"Ordo","5",[22,73,135,197,232,267,302,337,372],{"name":23,"value":7,"add_value":24,"describe":25,"children":26},"Home & Indoor","sofa","AI enhances everyday home life. Our datasets cover real indoor scenes to support smart devices, robotics, and home intelligence.",[27,29,31,33,35,37,40,43,46,49,52,55,58,61,64,67,70],{"name":28,"value":7},"Living Room",{"name":30,"value":11},"Bedroom",{"name":32,"value":14},"Kitchen",{"name":34,"value":17},"Dining Area",{"name":36,"value":20},"Bathroom",{"name":38,"value":39},"Entrance \u002F Foyer","6",{"name":41,"value":42},"Corridor \u002F Hallway","7",{"name":44,"value":45},"Staircase","8",{"name":47,"value":48},"Home Office","9",{"name":50,"value":51},"Hobby \u002F Game Room","10",{"name":53,"value":54},"Worship Space","11",{"name":56,"value":57},"Garage","12",{"name":59,"value":60},"Utility \u002F Laundry Room","13",{"name":62,"value":63},"Pantry","14",{"name":65,"value":66},"Basement","15",{"name":68,"value":69},"Garden","16",{"name":71,"value":72},"Balcony","17",{"name":74,"value":11,"add_value":75,"describe":76,"children":77},"Office & Educational","workshop","AI is reshaping work and learning. Our datasets capture offices and classrooms to power automation and next-generation productivity tools.",[78,81,84,87,90,93,96,99,102,105,108,111,114,117,120,123,126,129,132],{"name":79,"value":80},"Open Office","18",{"name":82,"value":83},"Private Office","19",{"name":85,"value":86},"Co-working Space","20",{"name":88,"value":89},"Reception \u002F Lobby","21",{"name":91,"value":92},"Conference Room","22",{"name":94,"value":95},"Huddle Room \u002F Booth","23",{"name":97,"value":98},"Lecture Hall \u002F Auditorium","24",{"name":100,"value":101},"Classroom","25",{"name":103,"value":104},"Science Laboratory","26",{"name":106,"value":107},"Library","27",{"name":109,"value":110},"Design Studio","28",{"name":112,"value":113},"Pantry \u002F Breakroom","29",{"name":115,"value":116},"Cafeteria \u002F Canteen","30",{"name":118,"value":119},"Restroom (Commercial)","31",{"name":121,"value":122},"Gymnasium \u002F Sports Hall","32",{"name":124,"value":125},"Server Room","33",{"name":127,"value":128},"Mailroom \u002F Logistics","34",{"name":130,"value":131},"Janitorial Closet","35",{"name":133,"value":134},"Corridor \u002F Elevators","36",{"name":136,"value":14,"add_value":137,"describe":138,"children":139},"Healthcare & Medical","love-and-help","AI is advancing modern healthcare. Our datasets include clinics and hospitals to enable clinical insights and medical automation.",[140,143,146,149,152,155,158,161,164,167,170,173,176,179,182,185,188,191,194],{"name":141,"value":142},"Operating Theatre \u002F OR","37",{"name":144,"value":145},"Consultation Room","38",{"name":147,"value":148},"Treatment Room","39",{"name":150,"value":151},"Dental Clinic","40",{"name":153,"value":154},"Inpatient Ward","41",{"name":156,"value":157},"Nurse Station","42",{"name":159,"value":160},"ICU","43",{"name":162,"value":163},"NICU (Neonatal ICU)","44",{"name":165,"value":166},"Emergency Room (ER)","45",{"name":168,"value":169},"Hospital Corridor","46",{"name":171,"value":172},"Waiting Area","47",{"name":174,"value":175},"CT\u002FMRI","48",{"name":177,"value":178},"Medical Laboratory","49",{"name":180,"value":181},"Phlebotomy Room","50",{"name":183,"value":184},"Rehabilitation Gym","51",{"name":186,"value":187},"Assisted Living Room","52",{"name":189,"value":190},"Pharmacy","53",{"name":192,"value":193},"Sterile Processing Dept","54",{"name":195,"value":196},"Medical Storage","55",{"name":198,"value":17,"add_value":199,"describe":200,"children":201},"Business & Public Service","business","AI is elevating commercial and public services. Our datasets span retail, dining, and service centers to improve intelligent operations.",[202,205,208,211,214,217,220,223,226,229],{"name":203,"value":204},"Shopping Mall Atrium","86",{"name":206,"value":207},"Supermarket Shelf","87",{"name":209,"value":210},"Self-Checkout Counter","88",{"name":212,"value":213},"Restaurant Dining Hall","89",{"name":215,"value":216},"Commercial Kitchen","90",{"name":218,"value":219},"Hotel Lobby","91",{"name":221,"value":222},"Subway Platform","92",{"name":224,"value":225},"Security Checkpoint","93",{"name":227,"value":228},"Underground Parking","94",{"name":230,"value":231},"Bank Teller Zone","95",{"name":233,"value":20,"add_value":234,"describe":235,"children":236},"Industrial & Manufacturing","robot-arm","AI is modernizing industry. Our datasets capture factories and logistics spaces to support robotics and intelligent manufacturing.",[237,240,243,246,249,252,255,258,261,264],{"name":238,"value":239},"Final Assembly Line","96",{"name":241,"value":242},"Quality Control Station","97",{"name":244,"value":245},"Robotic Welding Cell","98",{"name":247,"value":248},"CNC Machining Center","99",{"name":250,"value":251},"Cleanroom","100",{"name":253,"value":254},"Automated Warehouse","101",{"name":256,"value":257},"Loading Dock","102",{"name":259,"value":260},"Sorting Center","103",{"name":262,"value":263},"Chemical Plant","104",{"name":265,"value":266},"Power Substation","105",{"name":268,"value":39,"add_value":269,"describe":270,"children":271},"Transportation & Driving","car","AI is revolutionizing mobility. Our datasets capture road networks, vehicle dynamics and traffic scenarios to support autonomous driving and intelligent transportation systems.",[272,275,278,281,284,287,290,293,296,299],{"name":273,"value":274},"Urban Intersection","56",{"name":276,"value":277},"Highway \u002F Expressway","57",{"name":279,"value":280},"Tunnel","58",{"name":282,"value":283},"Roundabout","59",{"name":285,"value":286},"School \u002F Hospital Zone","60",{"name":288,"value":289},"Toll Station","61",{"name":291,"value":292},"Construction Zone","62",{"name":294,"value":295},"Parking Garage","63",{"name":297,"value":298},"Driver Cabin","64",{"name":300,"value":301},"Adverse Weather","65",{"name":303,"value":42,"add_value":304,"describe":305,"children":306},"Outdoor & Construction","tent-tree","AI is optimizing outdoor operations. Our datasets capture construction sites, open-air work zones and outdoor infrastructure to support smart construction and autonomous outdoor machinery.",[307,310,313,316,319,322,325,328,331,334],{"name":308,"value":309},"Excavation Site","66",{"name":311,"value":312},"Scaffolding Area","67",{"name":314,"value":315},"Material Storage Yard","68",{"name":317,"value":318},"Site Entrance","69",{"name":320,"value":321},"Roadwork Zone","70",{"name":323,"value":324},"Bridge Infrastructure","71",{"name":326,"value":327},"Transmission Line","72",{"name":329,"value":330},"Open-pit Mine","73",{"name":332,"value":333},"Tunneling Site","74",{"name":335,"value":336},"Post-Disaster Rubble","75",{"name":338,"value":45,"add_value":339,"describe":340,"children":341},"Nature, Aerial & Aquatic","global-loop","AI is exploring the natural world. Our datasets capture terrestrial landscapes, aerial vistas and aquatic ecosystems to support environmental monitoring and autonomous exploration systems.",[342,345,348,351,354,357,360,363,366,369],{"name":343,"value":344},"Deep Forest","76",{"name":346,"value":347},"Farmland \u002F Crops","77",{"name":349,"value":350},"River \u002F Lake","78",{"name":352,"value":353},"Open Ocean","79",{"name":355,"value":356},"Underwater Coral Reef","80",{"name":358,"value":359},"Fish Farm","81",{"name":361,"value":362},"Mountain Terrain","82",{"name":364,"value":365},"Urban Low Altitude","83",{"name":367,"value":368},"Fire Scene","84",{"name":370,"value":371},"Desert \u002F Gobi","85",{"name":373,"value":48,"add_value":374,"describe":375,"children":376},"Virtul & Digital","siri","AI is reshaping the virtual realm. Our datasets capture digital twins, virtual environments and simulated spaces to support metaverse development and intelligent digital interaction.",[377,380,383,386,389,392,395,398,401,404],{"name":378,"value":379},"VR Social Space","106",{"name":381,"value":382},"Synthetic Driving Sim","107",{"name":384,"value":385},"Digital Twin City","108",{"name":387,"value":388},"FPS \u002F MOBA Game","109",{"name":390,"value":391},"Robotics Gym","110",{"name":393,"value":394},"AR Navigation","111",{"name":396,"value":397},"Virtual Showroom","112",{"name":399,"value":400},"Code \u002F IDE Interface","113",{"name":402,"value":403},"App GUI Screen","114",{"name":405,"value":406},"Synthetic Face\u002FID","115",[408,411,414,417,420,423,426,429,432,435,438],{"name":409,"value":7,"add_value":410,"describe":8},"Classification","rubric",{"name":412,"value":11,"add_value":413,"describe":8},"Detection","radar",{"name":415,"value":14,"add_value":416,"describe":8},"Segmentation","segmentation",{"name":418,"value":17,"add_value":419,"describe":8},"Tacking","crosshairs",{"name":421,"value":20,"add_value":422,"describe":8},"Estimation","streamline",{"name":424,"value":39,"add_value":425,"describe":8},"QA","qa",{"name":427,"value":42,"add_value":428,"describe":8},"Recognition","finger-scan",{"name":430,"value":45,"add_value":431,"describe":8},"Control","control",{"name":433,"value":48,"add_value":434,"describe":8},"Extraction","extraction",{"name":436,"value":51,"add_value":437,"describe":8},"Retrieval","retrieval",{"name":439,"value":54,"add_value":440,"describe":8},"Forecast","forecast",[442,445,448,451,454,457,460,463,466,469,472,475],{"name":443,"value":7,"add_value":444,"describe":8},"Audio","audio",{"name":446,"value":11,"add_value":447,"describe":8},"Image","image",{"name":449,"value":14,"add_value":450,"describe":8},"Text","text",{"name":452,"value":17,"add_value":453,"describe":8},"Video","video",{"name":455,"value":20,"add_value":456,"describe":8},"Multi","multi",{"name":458,"value":39,"add_value":459,"describe":8},"Document","document",{"name":461,"value":42,"add_value":462,"describe":8},"Time-Series","time-series",{"name":464,"value":45,"add_value":465,"describe":8},"3D cloud","cloud",{"name":467,"value":48,"add_value":468,"describe":8},"Code","code",{"name":470,"value":51,"add_value":471,"describe":8},"Event","event",{"name":473,"value":54,"add_value":474,"describe":8},"Motion","motion",{"name":476,"value":57,"add_value":477,"describe":8},"Interaction","interaction",[479,482,487,491,494,499,504,509,514,519,524,528,532,536,540,544,548,552,556,559],{"id":480,"value":480,"name":233,"intro":481,"add_value":234,"describe":481},2,"智能质检：利用图像识别、多模态模型对产品外观或声音、振动等数据进行分析，自动识别缺陷，提高质量控制效率。\n工业知识问答与文档理解：通过大模型理解和总结技术文档、操作手册，实现快速问答、知识检索和培训支持。\n安全监测与风险预警：实时分析视频、传感器和操作日志，识别潜在危险行为或异常状态，提前预警，保障人员和设备安全。",{"id":483,"value":483,"name":484,"intro":485,"add_value":486,"describe":485},3,"Finance & Insurance","风险评估与预测：分析大量客户数据，评估信用风险、市场风险等，预测违约概率、股价走势等，辅助金融机构决策。\n智能投顾：根据客户风险偏好、资产状况等，提供个性化投资组合建议，实时调整投资策略。\n反欺诈检测：通过分析交易数据、用户行为，识别异常交易和欺诈行为，保障金融安全。","funds",{"id":488,"value":488,"name":489,"intro":490,"add_value":269,"describe":490},1,"Transport & Automotive","智能座舱：打造多模态交互的 AI 座舱，通过语音、手势、面部识别等实现人机交互，如语音控制导航、音乐播放。\n驾驶员状态监测：识别疲劳、分心、抽烟、打电话等行为，通过大模型判断危险等级，触发相应提醒或干预机制。\n智能驾驶：AI 用于环境感知、路径规划与决策控制，使车辆能识别道路、行人、障碍物等，实现自适应巡航、自动泊车、车道保持等功能，提升驾驶安全性与便利性。",{"id":492,"value":492,"name":136,"intro":493,"add_value":137,"describe":493},4,"医学影像诊断：分析 CT、MRI 等影像，辅助医生检测疾病、识别病灶，如 AI 系统可快速发现肺部结节。\n医患对话助手：通过自然语言处理理解患者问题，提供初步健康建议或就诊指导，缓解医生接诊压力。\n智能健康管理：根据用户健康数据，提供个性化健康建议、疾病预警，如智能手环结合 AI 分析用户运动、睡眠、心率等数据。",{"id":495,"value":495,"name":496,"intro":497,"add_value":498,"describe":497},6,"Smart Devices","多模态交互：支持语音、手势、眼神等多种交互方式，如 AI 眼镜可通过语音指令实现翻译、搜索功能。\n智能感知与处理：使设备能感知环境、理解用户需求，如智能音箱根据环境噪音自动调节音量。\n个性化服务：根据用户使用习惯和偏好，提供个性化功能与服务，如智能手表为用户定制运动健身计划。","microscope",{"id":500,"value":500,"name":501,"intro":502,"add_value":503,"describe":502},8,"Law & Government","智能法律问答：面向公众或企业用户，提供合规、劳动法、婚姻继承、知识产权等常见法律问题的智能解答。\n合同审查与风险识别：利用大模型分析合同内容，识别潜在风险条款、漏洞或不合理约定，提升合同审核质量。\n法律知识图谱构建：自动梳理法规、案例、条文之间的引用关系，构建语义化知识图谱，支持智能分析和推理。","hammer",{"id":505,"value":505,"name":506,"intro":507,"add_value":508,"describe":507},7,"Education & Training","个性化学习：根据学生学习进度、能力和知识掌握情况，推送个性化学习内容与练习，如智能辅导系统为学生制定专属学习计划。\n智能教学辅助：AI 助教协助教师进行作业批改、答疑解惑，还可分析教学数据，为教师提供教学反馈，优化教学方法。\n虚拟学习环境：利用 AI 创建虚拟实验、历史场景等，让学生沉浸式学习，如在虚拟化学实验室中进行实验操作。","degree-hat",{"id":510,"value":510,"name":511,"intro":512,"add_value":513,"describe":512},5,"Agriculture & Food","作物病虫害识别与防治：通过图像识别分析农作物叶片、果实等症状，识别病虫害类型，给出防治建议，减少产量损失。\n农产品质量检测：利用图像和传感器数据，识别果蔬等农产品的成熟度、外观缺陷，进行自动分级，提高市场竞争力。\n农情监测与预测：利用卫星遥感、气象和传感器数据，结合大模型预测作物长势、干旱、洪涝等农情变化。","ph-farm",{"id":515,"value":515,"name":516,"intro":517,"add_value":518,"describe":517},9,"Retail & E-commerce","智能客服：通过自然语言对话理解用户需求，提供产品推荐、订单查询、退换货支持等服务，提升客户满意度。\n个性化营销推荐：基于用户浏览、购买、偏好等行为数据，生成个性化推荐内容与优惠策略，提高转化率和客单价。\n商品内容生成：自动撰写商品标题、卖点描述、使用说明等内容，适用于海量SKU的内容生产与多语言发布。","buy",{"id":520,"value":520,"name":521,"intro":522,"add_value":523,"describe":8},10,"Security & Protection",null,"safe-shield-line",{"id":525,"value":525,"name":526,"intro":522,"add_value":527,"describe":8},11,"Environment & Climate","weather",{"id":529,"value":529,"name":530,"intro":522,"add_value":531,"describe":8},12,"Energy & Resource","energy-leaf",{"id":533,"value":533,"name":534,"intro":522,"add_value":535,"describe":8},13,"Express & Logistics","speed-outline",{"id":537,"value":537,"name":538,"intro":522,"add_value":539,"describe":8},15,"Sports","baseball-outline",{"id":541,"value":541,"name":542,"intro":522,"add_value":543,"describe":8},16,"General Data","daily-booth",{"id":545,"value":545,"name":546,"intro":522,"add_value":547,"describe":8},17,"Content & Media","media",{"id":549,"value":549,"name":550,"intro":522,"add_value":551,"describe":8},18,"Construction","construction",{"id":553,"value":553,"name":554,"intro":522,"add_value":555,"describe":8},19,"IT & Telecom","tech",{"id":557,"value":557,"name":558,"intro":522,"add_value":498,"describe":8},20,"Science & Research",{"id":560,"value":560,"name":561,"intro":522,"add_value":562,"describe":8},21,"Language & Culture","lang",{"id":564,"unique_code":565,"title":566,"icon":8,"intro":567,"cate":483,"detail":568,"create_time":569,"update_time":570,"price":571,"view_count":560,"download_count":572,"unit":572,"amount":573,"is_create_order":572,"enterprise_id":488,"seo_keywords":574,"seo_description":575,"data_format":576,"file_size":577,"apply_scene":578,"training_task":579,"version":580,"dataset_type_id":492,"dataset_scene_id":500,"sample_file":581,"banner":8,"unit_name":8,"cate_name":449,"icon_url":8,"banner_url":8,"sample_file_url":8,"data_dict":582,"qa_list":641,"sample_metadatas":658,"text_sample_content":707,"enterprise_name":708,"enterprise_logo":709,"data_distribution":710},1274,"6a3a802ebebdbae364c831e4f1f8f2b3","Life Sciences Intellectual Property Licensing Contract QA Dataset","Train evidence-grounded legal AI on life sciences licensing contracts and their core commercial and rights provisions.","\u003Cp>This dataset contains closed-domain question-answer pairs grounded in intellectual property licensing contracts for biotechnology, drug development, and diagnostic technologies. Topics include indications and licensed fields, development and registration responsibilities, milestones, sales royalties, patent maintenance, data use, and commercialization rights. Records include contract text, questions, expert answers, and supporting clauses, with structured information on licensing scope, responsibilities, and commercial terms for legal AI training, clause analysis, and transaction review.\u003C\u002Fp>","2026-10-15 19:28:29","2026-10-19 17:18:38","0.00",0,5000,"life sciences licensing contracts,IP licensing question answering,biotechnology contract dataset,drug development licensing,contract clause QA,license scope analysis,contract evidence retrieval,legal AI training","Evidence-grounded Q&A for life sciences licensing contracts, covering key rights, responsibilities, commercial terms, and clauses for legal AI training and deal","JSON","0.4GB","life sciences licensing, intellectual property contract review, technology commercialization","contract question answering, clause interpretation, rights and commercial term analysis","V1.0","rivo\u002Fsample-packages\u002F9d55e7ac-9ab9-4404-a621-5c6649490e9d\u002F20261015.zip",[583,588,593,598,603,609,614,620,626,631,636],{"id":572,"name":584,"field":585,"intro":586,"type":587},"File Name","file_name","File name","string",{"id":589,"name":590,"field":591,"intro":592,"type":587},9369,"Answer","answer","An accurate, complete, and professionally written response to the question based on the contract text.",{"id":594,"name":595,"field":596,"intro":597,"type":587},9370,"User Question","question","A specific question about indications, licensed fields, development and registration responsibilities, milestones, sales royalties, patent maintenance, data use, or commercialization rights.",{"id":599,"name":600,"field":601,"intro":602,"type":587},9371,"Contract Text","contract_text","The full text of the intellectual property licensing contract, or the relevant contract clauses used as the basis for question answering.",{"id":604,"name":605,"field":606,"intro":607,"type":608},9372,"License Scope","license_scope","Indications, technical fields, territorial scope, exclusivity, and authorized rights extracted from the contract.","object",{"id":610,"name":611,"field":612,"intro":613,"type":608},9373,"Commercial and Economic Terms","commercial_terms","Economic arrangements covering sales royalties, license fees, milestone payments, payment bases, and sales reporting.",{"id":615,"name":616,"field":617,"intro":618,"type":619},9374,"Evidence Clauses","evidence_clauses","Contract clauses, sections, or excerpts that support the answer.","array",{"id":621,"name":622,"field":623,"intro":624,"type":625},9375,"Answer Confidence","answer_confidence","A confidence score from 0 to 1 based on the completeness of contract evidence, clarity of the clauses, and alignment between the question and its supporting evidence.","number",{"id":627,"name":628,"field":629,"intro":630,"type":587},9376,"Question Category","question_category","A standardized category for the licensing contract topic addressed by the question.",{"id":632,"name":633,"field":634,"intro":635,"type":608},9377,"Patent, Data, and Commercialization Rights","patent_and_data_rights","Rights and obligations concerning patent filing and maintenance, patent costs, use of development data, commercialization, and sublicensing.",{"id":637,"name":638,"field":639,"intro":640,"type":608},9378,"Development and Registration Responsibilities","development_and_registration_responsibilities","The parties' responsibilities and related costs for development, clinical trials, regulatory submissions, and registration approvals.",[642,646,650,654],{"id":643,"question":644,"answer":645},6547,"What does the dataset contain?","Records are grounded in full licensing contracts or relevant clauses and include contract text, a user question, an answer, and supporting evidence clauses. They may also include structured fields for question category, license scope, development and registration responsibilities, commercial terms, and patent and data rights.",{"id":647,"question":648,"answer":649},6548,"What capabilities can it support?","It can support training and evaluation for closed-domain question answering, contract clause retrieval, evidence-grounded responses, and domain-specific supervised fine-tuning. It can also assist with contract topic classification and extraction of key obligations.",{"id":651,"question":652,"answer":653},6549,"How can I obtain the dataset and verify its specifications?","Check the dataset product page or contact the provider for available versions. Confirm record count, file format, field coverage, and delivery method from the published listing, as these specifications may vary by version.",{"id":655,"question":656,"answer":657},6550,"What licensing considerations apply?","Before use, verify the dataset license, commercial-use permissions, and redistribution restrictions. Ensure that contract texts and related materials are authorized for use. For actual transactions or legal decisions, review the complete contract with qualified professionals.",[659,677,692],{"id":660,"relate_table":661,"relate_id":662,"file_size":572,"file_name":663,"path":8,"duration":572,"cate":483,"file_format":664,"audio_rate":8,"audio_channel":522,"audio_bit_depth":522,"quality":8,"annotation":665,"cate_name":666,"answer":667,"question":668,"contract_text":669,"license_scope":670,"commercial_terms":671,"evidence_clauses":672,"answer_confidence":673,"question_category":674,"patent_and_data_rights":675,"development_and_registration_responsibilities":676},15222,"union_cubo",1008988424,"样例_3.json","json","{\"answer\": \"Within the licensed field, Party B may use, copy, and analyze clinical data, pharmacological and toxicological data, process data, and registration materials, and may submit data necessary for contract performance to regulatory authorities, or provide it to CROs, regulatory consultants, and Party A-approved sublicensees bound by confidentiality obligations. Original data records shall be kept by the party that generates them. Party A may access de-identified data generated by Party B for platform safety evaluation, patent maintenance, and basic research outside the licensed field, but may not provide identifiable personal information to any third party, nor use Party B's confidential clinical data to develop competitive products within the licensed field.\", \"question\": \"Regarding the clinical and R&D data generated by the ZX-7 project, how may Party B use or provide it to third parties? What access and use rights does Party A have?\", \"contract_text\": \"Party A is Yaochen Gene Technology Co., Ltd., and Party B is Yuanchuan Biopharmaceutical Co., Ltd. Article 1: Party A grants Party B an exclusive license worldwide to research and develop, clinically develop, register, manufacture, import, promote, sell, and distribute products using the ZX-7 base editing delivery platform and its improvements for hereditary retinal diseases. The licensed field includes Leber congenital amaurosis, retinitis pigmentosa, and other hereditary retinal diseases listed in the contract annex. Article 2: Party B may disclose technology and data necessary for contract performance to CROs, CMOs, regulatory consultants, and Party A-approved commercial partners bound by confidentiality obligations, and may grant sublicenses after obtaining Party A's written consent. Article 3: Party A shall deliver the platform technology package, vector construction plans, existing in vitro and animal study data, analytical methods, and patent documents, and shall provide technical consultation on Party B's preclinical plans. Article 4: Party B is responsible for preclinical studies, clinical trials, subject protection, regulatory submissions, manufacturing process development, commercialization, and related costs. Both parties are jointly responsible for developing the data management plan, sample coding rules, and serious adverse event reporting procedures. Article 5: Party B shall complete the clinical trial application for the first candidate product within 15 months from the effective date, complete first subject dosing within 36 months, and submit the marketing authorization application for the first indication within 60 months. Article 6: Party B shall pay a milestone payment of USD 2,000,000 when the first indication obtains marketing authorization; after product launch, Party B shall pay a 5% sales royalty on global net sales. Article 7: Party A is responsible for filing, maintaining, and litigation strategy for the platform basic patents, and Party B bears 70% of global basic patent costs; product patents independently developed by Party B are Party B's responsibility, and Party A enjoys a royalty-free right to use them within the licensed field. Article 8.1: Original records of clinical data, pharmacological and toxicological data, process data, and registration materials shall be kept by the party that generates them, and Party B has the right within the licensed field to use, copy, analyze, submit to regulatory authorities, and provide such data to approved sublicensees. Article 8.2: Party A may access de-identified data generated by Party B for platform safety evaluation, patent maintenance, and basic research outside the licensed field, but may not provide identifiable personal information to any third party, nor use Party B's confidential clinical data to develop competitive products within the licensed field. Article 9: Party B is responsible for global commercialization, supply chain, marketing, sales, and pharmacovigilance of the product, and shall report net sales to Party A quarterly.\", \"license_scope\": \"{\\\"indications_or_fields\\\": [\\\"Leber congenital amaurosis\\\", \\\"Retinitis pigmentosa\\\", \\\"Other hereditary retinal diseases listed in the contract annex\\\"], \\\"territory\\\": \\\"Worldwide\\\", \\\"exclusivity\\\": \\\"Exclusive license\\\", \\\"licensed_rights\\\": [\\\"Preclinical research and development\\\", \\\"Clinical development\\\", \\\"Regulatory submissions\\\", \\\"Manufacturing\\\", \\\"Import\\\", \\\"Promotion\\\", \\\"Sales\\\", \\\"Distribution\\\", \\\"Sublicensing after Party A's written consent\\\"]}\", \"commercial_terms\": \"{\\\"royalty_terms\\\": [{\\\"rate\\\": 5, \\\"rate_unit\\\": \\\"percent\\\", \\\"royalty_base\\\": \\\"global net sales of the product\\\", \\\"tier_condition\\\": \\\"Applies uniformly to global net sales after all licensed products are launched.\\\"}], \\\"milestone_payments\\\": [{\\\"amount\\\": 2000000, \\\"currency\\\": \\\"USD\\\", \\\"triggering_event\\\": \\\"The first licensed indication obtains marketing authorization.\\\"}], \\\"sales_reporting_requirements\\\": [\\\"Party B shall report global net sales to Party A quarterly\\\", \\\"Submit sales reports and pay accrued sales royalties within 45 days after the end of the quarter\\\", \\\"Sales reports shall distinguish by indication, country, and product specification\\\"]}\", \"evidence_clauses\": \"[{\\\"clause_reference\\\": \\\"Article 8.1\\\", \\\"excerpt\\\": \\\"Party B has the right within the licensed field to use, copy, analyze, submit to regulatory authorities, and provide clinical data, pharmacological and toxicological data, process data, and registration materials to approved sublicensees.\\\", \\\"evidence_explanation\\\": \\\"This clause clarifies Party B's scope of use of project data, right to make regulatory submissions, and authority to provide data to approved third parties, and limits use to the licensed field.\\\"}, {\\\"clause_reference\\\": \\\"Article 8.2\\\", \\\"excerpt\\\": \\\"Party A may access de-identified data generated by Party B for platform safety evaluation, patent maintenance, and basic research outside the licensed field, but may not provide identifiable personal information to any third party, nor use Party B's confidential clinical data to develop competitive products within the licensed field.\\\", \\\"evidence_explanation\\\": \\\"This clause sets out Party A's data access purposes and boundaries, including de-identification requirements, permitted uses, and restrictions on disclosing personal information and conducting competitive development.\\\"}, {\\\"clause_reference\\\": \\\"Article 2\\\", \\\"excerpt\\\": \\\"Party B may disclose technology and data necessary for contract performance to CROs, CMOs, regulatory consultants, and Party A-approved commercial partners bound by confidentiality obligations.\\\", \\\"evidence_explanation\\\": \\\"This clause supplements the scope of recipients and preconditions for Party B to provide data to external service providers, namely that it is necessary for contract performance, confidentiality obligations are assumed, and Party A's approval is obtained in sublicensing scenarios.\\\"}]\", \"answer_confidence\": \"0.97\", \"question_category\": \"Data Use Rights\", \"patent_and_data_rights\": \"{\\\"patent_maintenance_party\\\": \\\"Party A is responsible for filing, maintaining, and litigation strategy for platform basic patents; Party B is responsible for product patents it independently develops.\\\", \\\"patent_cost_allocation\\\": \\\"Party B bears 70% of global basic patent costs; costs for product patents independently developed by Party B shall be borne by Party B.\\\", \\\"data_use_rights\\\": [\\\"Party B may use, copy, and analyze clinical and R&D data within the licensed field\\\", \\\"Party B may submit data and registration materials to regulatory authorities\\\", \\\"Party B may provide data necessary for contract performance to CROs, regulatory consultants, and approved sublicensees bound by confidentiality obligations\\\", \\\"Party A may access de-identified data generated by Party B for platform safety evaluation, patent maintenance, and basic research outside the licensed field\\\", \\\"Party A may not disclose identifiable personal information or use Party B's confidential clinical data to develop competitive products within the licensed field\\\"], \\\"commercialization_rights\\\": [\\\"Party B has global product manufacturing rights\\\", \\\"Party B has global promotion, sales, and distribution rights\\\", \\\"Party B is responsible for the global supply chain and post-marketing pharmacovigilance\\\"], \\\"sublicensing_rights\\\": \\\"Party B may disclose data necessary for contract performance to service providers bound by confidentiality obligations; granting sublicenses to commercial partners requires prior written consent from Party A, and Party B must ensure that sublicensees assume data protection and reporting obligations no less stringent than those in this contract.\\\"}\", \"development_and_registration_responsibilities\": \"{\\\"licensor_responsibilities\\\": [\\\"Deliver the platform technology package, vector construction plans, and existing research data\\\", \\\"Provide analytical methods and patent documents\\\", \\\"Provide technical consultation on preclinical plans\\\", \\\"Responsible for filing, maintaining, and litigation strategy for platform basic patents\\\", \\\"Access de-identified data for platform safety evaluation and patent maintenance\\\"], \\\"licensee_responsibilities\\\": [\\\"Responsible for preclinical studies and clinical trials\\\", \\\"Responsible for subject protection and safety reporting\\\", \\\"Responsible for regulatory submissions\\\", \\\"Responsible for manufacturing process development\\\", \\\"Bear commercialization and related R&D costs\\\", \\\"Responsible for global product supply chain, promotion, sales, and pharmacovigilance\\\"], \\\"shared_responsibilities\\\": [\\\"Jointly develop the data management plan\\\", \\\"Jointly develop sample coding rules\\\", \\\"Jointly develop serious adverse event reporting procedures\\\", \\\"Jointly comply with applicable data protection and clinical trial regulations\\\"], \\\"milestones\\\": [{\\\"milestone_name\\\": \\\"Submit clinical trial application for first candidate product\\\", \\\"milestone_type\\\": \\\"Regulatory submission\\\", \\\"responsible_party\\\": \\\"Party B, Yuanchuan Biopharmaceutical Co., Ltd., with Party A providing technical materials and consultation\\\", \\\"target_date\\\": \\\"Within 15 months from the effective date of the contract\\\", \\\"completion_condition\\\": \\\"Complete integration of preclinical materials and submit a clinical trial application to the competent regulatory authority.\\\"}, {\\\"milestone_name\\\": \\\"First subject dosing\\\", \\\"milestone_type\\\": \\\"Clinical trial\\\", \\\"responsible_party\\\": \\\"Party B, Yuanchuan Biopharmaceutical Co., Ltd.\\\", \\\"target_date\\\": \\\"Within 36 months from the effective date of the contract\\\", \\\"completion_condition\\\": \\\"Complete first subject dosing under the approved clinical trial protocol and form traceable records.\\\"}, {\\\"milestone_name\\\": \\\"Submit marketing authorization application for first indication\\\", \\\"milestone_type\\\": \\\"Regulatory submission\\\", \\\"responsible_party\\\": \\\"Party B, Yuanchuan Biopharmaceutical Co., Ltd.\\\", \\\"target_date\\\": \\\"Within 60 months from the effective date of the contract\\\", \\\"completion_condition\\\": \\\"Submit a complete marketing authorization application for the first licensed indication to the applicable regulatory authority.\\\"}]}\"}","文本","Within the licensed field, Party B may use, copy, and analyze clinical data, pharmacological and toxicological data, process data, and registration materials, and may submit data necessary for contract performance to regulatory authorities, or provide it to CROs, regulatory consultants, and Party A-approved sublicensees bound by confidentiality obligations. Original data records shall be kept by the party that generates them. Party A may access de-identified data generated by Party B for platform safety evaluation, patent maintenance, and basic research outside the licensed field, but may not provide identifiable personal information to any third party, nor use Party B's confidential clinical data to develop competitive products within the licensed field.","Regarding the clinical and R&D data generated by the ZX-7 project, how may Party B use or provide it to third parties? What access and use rights does Party A have?","Party A is Yaochen Gene Technology Co., Ltd., and Party B is Yuanchuan Biopharmaceutical Co., Ltd. Article 1: Party A grants Party B an exclusive license worldwide to research and develop, clinically develop, register, manufacture, import, promote, sell, and distribute products using the ZX-7 base editing delivery platform and its improvements for hereditary retinal diseases. The licensed field includes Leber congenital amaurosis, retinitis pigmentosa, and other hereditary retinal diseases listed in the contract annex. Article 2: Party B may disclose technology and data necessary for contract performance to CROs, CMOs, regulatory consultants, and Party A-approved commercial partners bound by confidentiality obligations, and may grant sublicenses after obtaining Party A's written consent. Article 3: Party A shall deliver the platform technology package, vector construction plans, existing in vitro and animal study data, analytical methods, and patent documents, and shall provide technical consultation on Party B's preclinical plans. Article 4: Party B is responsible for preclinical studies, clinical trials, subject protection, regulatory submissions, manufacturing process development, commercialization, and related costs. Both parties are jointly responsible for developing the data management plan, sample coding rules, and serious adverse event reporting procedures. Article 5: Party B shall complete the clinical trial application for the first candidate product within 15 months from the effective date, complete first subject dosing within 36 months, and submit the marketing authorization application for the first indication within 60 months. Article 6: Party B shall pay a milestone payment of USD 2,000,000 when the first indication obtains marketing authorization; after product launch, Party B shall pay a 5% sales royalty on global net sales. Article 7: Party A is responsible for filing, maintaining, and litigation strategy for the platform basic patents, and Party B bears 70% of global basic patent costs; product patents independently developed by Party B are Party B's responsibility, and Party A enjoys a royalty-free right to use them within the licensed field. Article 8.1: Original records of clinical data, pharmacological and toxicological data, process data, and registration materials shall be kept by the party that generates them, and Party B has the right within the licensed field to use, copy, analyze, submit to regulatory authorities, and provide such data to approved sublicensees. Article 8.2: Party A may access de-identified data generated by Party B for platform safety evaluation, patent maintenance, and basic research outside the licensed field, but may not provide identifiable personal information to any third party, nor use Party B's confidential clinical data to develop competitive products within the licensed field. Article 9: Party B is responsible for global commercialization, supply chain, marketing, sales, and pharmacovigilance of the product, and shall report net sales to Party A quarterly.","{\"indications_or_fields\": [\"Leber congenital amaurosis\", \"Retinitis pigmentosa\", \"Other hereditary retinal diseases listed in the contract annex\"], \"territory\": \"Worldwide\", \"exclusivity\": \"Exclusive license\", \"licensed_rights\": [\"Preclinical research and development\", \"Clinical development\", \"Regulatory submissions\", \"Manufacturing\", \"Import\", \"Promotion\", \"Sales\", \"Distribution\", \"Sublicensing after Party A's written consent\"]}","{\"royalty_terms\": [{\"rate\": 5, \"rate_unit\": \"percent\", \"royalty_base\": \"global net sales of the product\", \"tier_condition\": \"Applies uniformly to global net sales after all licensed products are launched.\"}], \"milestone_payments\": [{\"amount\": 2000000, \"currency\": \"USD\", \"triggering_event\": \"The first licensed indication obtains marketing authorization.\"}], \"sales_reporting_requirements\": [\"Party B shall report global net sales to Party A quarterly\", \"Submit sales reports and pay accrued sales royalties within 45 days after the end of the quarter\", \"Sales reports shall distinguish by indication, country, and product specification\"]}","[{\"clause_reference\": \"Article 8.1\", \"excerpt\": \"Party B has the right within the licensed field to use, copy, analyze, submit to regulatory authorities, and provide clinical data, pharmacological and toxicological data, process data, and registration materials to approved sublicensees.\", \"evidence_explanation\": \"This clause clarifies Party B's scope of use of project data, right to make regulatory submissions, and authority to provide data to approved third parties, and limits use to the licensed field.\"}, {\"clause_reference\": \"Article 8.2\", \"excerpt\": \"Party A may access de-identified data generated by Party B for platform safety evaluation, patent maintenance, and basic research outside the licensed field, but may not provide identifiable personal information to any third party, nor use Party B's confidential clinical data to develop competitive products within the licensed field.\", \"evidence_explanation\": \"This clause sets out Party A's data access purposes and boundaries, including de-identification requirements, permitted uses, and restrictions on disclosing personal information and conducting competitive development.\"}, {\"clause_reference\": \"Article 2\", \"excerpt\": \"Party B may disclose technology and data necessary for contract performance to CROs, CMOs, regulatory consultants, and Party A-approved commercial partners bound by confidentiality obligations.\", \"evidence_explanation\": \"This clause supplements the scope of recipients and preconditions for Party B to provide data to external service providers, namely that it is necessary for contract performance, confidentiality obligations are assumed, and Party A's approval is obtained in sublicensing scenarios.\"}]","0.97","Data Use Rights","{\"patent_maintenance_party\": \"Party A is responsible for filing, maintaining, and litigation strategy for platform basic patents; Party B is responsible for product patents it independently develops.\", \"patent_cost_allocation\": \"Party B bears 70% of global basic patent costs; costs for product patents independently developed by Party B shall be borne by Party B.\", \"data_use_rights\": [\"Party B may use, copy, and analyze clinical and R&D data within the licensed field\", \"Party B may submit data and registration materials to regulatory authorities\", \"Party B may provide data necessary for contract performance to CROs, regulatory consultants, and approved sublicensees bound by confidentiality obligations\", \"Party A may access de-identified data generated by Party B for platform safety evaluation, patent maintenance, and basic research outside the licensed field\", \"Party A may not disclose identifiable personal information or use Party B's confidential clinical data to develop competitive products within the licensed field\"], \"commercialization_rights\": [\"Party B has global product manufacturing rights\", \"Party B has global promotion, sales, and distribution rights\", \"Party B is responsible for the global supply chain and post-marketing pharmacovigilance\"], \"sublicensing_rights\": \"Party B may disclose data necessary for contract performance to service providers bound by confidentiality obligations; granting sublicenses to commercial partners requires prior written consent from Party A, and Party B must ensure that sublicensees assume data protection and reporting obligations no less stringent than those in this contract.\"}","{\"licensor_responsibilities\": [\"Deliver the platform technology package, vector construction plans, and existing research data\", \"Provide analytical methods and patent documents\", \"Provide technical consultation on preclinical plans\", \"Responsible for filing, maintaining, and litigation strategy for platform basic patents\", \"Access de-identified data for platform safety evaluation and patent maintenance\"], \"licensee_responsibilities\": [\"Responsible for preclinical studies and clinical trials\", \"Responsible for subject protection and safety reporting\", \"Responsible for regulatory submissions\", \"Responsible for manufacturing process development\", \"Bear commercialization and related R&D costs\", \"Responsible for global product supply chain, promotion, sales, and pharmacovigilance\"], \"shared_responsibilities\": [\"Jointly develop the data management plan\", \"Jointly develop sample coding rules\", \"Jointly develop serious adverse event reporting procedures\", \"Jointly comply with applicable data protection and clinical trial regulations\"], \"milestones\": [{\"milestone_name\": \"Submit clinical trial application for first candidate product\", \"milestone_type\": \"Regulatory submission\", \"responsible_party\": \"Party B, Yuanchuan Biopharmaceutical Co., Ltd., with Party A providing technical materials and consultation\", \"target_date\": \"Within 15 months from the effective date of the contract\", \"completion_condition\": \"Complete integration of preclinical materials and submit a clinical trial application to the competent regulatory authority.\"}, {\"milestone_name\": \"First subject dosing\", \"milestone_type\": \"Clinical trial\", \"responsible_party\": \"Party B, Yuanchuan Biopharmaceutical Co., Ltd.\", \"target_date\": \"Within 36 months from the effective date of the contract\", \"completion_condition\": \"Complete first subject dosing under the approved clinical trial protocol and form traceable records.\"}, {\"milestone_name\": \"Submit marketing authorization application for first indication\", \"milestone_type\": \"Regulatory submission\", \"responsible_party\": \"Party B, Yuanchuan Biopharmaceutical Co., Ltd.\", \"target_date\": \"Within 60 months from the effective date of the contract\", \"completion_condition\": \"Submit a complete marketing authorization application for the first licensed indication to the applicable regulatory authority.\"}]}",{"id":678,"relate_table":661,"relate_id":679,"file_size":572,"file_name":680,"path":8,"duration":572,"cate":483,"file_format":664,"audio_rate":8,"audio_channel":522,"audio_bit_depth":522,"quality":8,"annotation":681,"cate_name":666,"answer":682,"question":683,"contract_text":684,"license_scope":685,"commercial_terms":686,"evidence_clauses":687,"answer_confidence":688,"question_category":689,"patent_and_data_rights":690,"development_and_registration_responsibilities":691},15221,1078641015,"样例_2.json","{\"answer\": \"Sales royalties are calculated based on annual net sales of the product and use progressive tiered rates: the portion of annual net sales not exceeding RMB 100,000,000 is calculated at 3%; the portion exceeding RMB 100,000,000 but not exceeding RMB 300,000,000 is calculated at 5%; the portion exceeding RMB 300,000,000 is calculated at 7%. Free research samples and validation samples provided to regulatory authorities in accordance with law are not included in net sales. Party B shall submit sales reports and royalty calculation statements within 30 days after the end of each quarter.\", \"question\": \"How are sales royalties for the multiplex respiratory pathogen PCR detection kit calculated? What rates apply to the different annual net sales tiers?\", \"contract_text\": \"Party A is Minglan Diagnostic Technology Research Institute, and Party B is Qiheng In Vitro Diagnostics Co., Ltd. Article 1: Party A licenses to Party B the multiplex respiratory pathogen PCR detection kit and its primer design, probe combination, and supporting analysis software technology. The licensed territory is mainland China, and the licensed field is limited to in vitro detection of respiratory pathogens in public hospitals, private hospitals, and third-party independent medical laboratories. Party B enjoys a partially exclusive license in hospital and independent medical laboratory scenarios, but Party A retains the right for internal research and non-commercial validation by scientific research institutions. Article 2: Party B obtains the right to research and develop, register, contract manufacture, sell, import, and distribute the kit within the licensed field. Without Party A's written consent, Party B may not sublicense to competitive in vitro diagnostic companies. Article 3: Party A shall provide a list of candidate pathogens, primer and probe sequences, performance validation reports, reference material preparation methods, and software interface documentation. Party B is responsible for product finalization, analytical performance validation, clinical evaluation, quality system construction, manufacturing filing or registration submission, and commercialization costs. Article 4: Party B shall complete analytical performance validation within 9 months from the effective date, submit registration application within 18 months, and obtain the applicable in vitro diagnostic product registration certificate within 30 months. Article 5: After obtaining the registration certificate, Party B shall pay Party A a registration milestone payment of RMB 800,000. Article 6.1: Party B shall pay sales royalties based on annual net sales of the product: for the portion of annual net sales not exceeding RMB 100,000,000, 3%; for the portion exceeding RMB 100,000,000 but not exceeding RMB 300,000,000, 5%; for the portion exceeding RMB 300,000,000, 7%. Free research samples and validation samples provided to regulatory authorities in accordance with law shall not be included in net sales. Article 7: Party A is responsible for filing and maintaining the basic patents and patents related to core sequences, and Party B is responsible for filing patents for independently developed improvements; the annual fees for the basic patents in the licensed territory shall be shared 50% by each party. Article 8: Party B may use validation data, clinical evaluation data, and registration materials for product registration, quality management, market access, and sales compliance, and Party A may access de-identified data for technical improvement and patent maintenance. Article 9: Party B shall submit sales reports and royalty calculation statements within 30 days after the end of each quarter, and shall retain relevant books and records for at least 7 years.\", \"license_scope\": \"{\\\"indications_or_fields\\\": [\\\"In vitro detection of respiratory pathogens in hospitals\\\", \\\"In vitro detection of respiratory pathogens in third-party independent medical laboratories\\\"], \\\"territory\\\": \\\"Mainland China\\\", \\\"exclusivity\\\": \\\"Partially exclusive license\\\", \\\"licensed_rights\\\": [\\\"Research and development\\\", \\\"Analytical performance validation\\\", \\\"Registration submissions\\\", \\\"Contract manufacturing\\\", \\\"Sales\\\", \\\"Import\\\", \\\"Distribution\\\"]}\", \"commercial_terms\": \"{\\\"royalty_terms\\\": [{\\\"rate\\\": 3, \\\"rate_unit\\\": \\\"percent\\\", \\\"royalty_base\\\": \\\"annual net sales of the product\\\", \\\"tier_condition\\\": \\\"The portion of annual net sales not exceeding RMB 100,000,000.\\\"}, {\\\"rate\\\": 5, \\\"rate_unit\\\": \\\"percent\\\", \\\"royalty_base\\\": \\\"annual net sales of the product\\\", \\\"tier_condition\\\": \\\"The portion of annual net sales exceeding RMB 100,000,000 but not exceeding RMB 300,000,000.\\\"}, {\\\"rate\\\": 7, \\\"rate_unit\\\": \\\"percent\\\", \\\"royalty_base\\\": \\\"annual net sales of the product\\\", \\\"tier_condition\\\": \\\"The portion of annual net sales exceeding RMB 300,000,000.\\\"}], \\\"milestone_payments\\\": [{\\\"amount\\\": 800000, \\\"currency\\\": \\\"RMB\\\", \\\"triggering_event\\\": \\\"Party B obtains the in vitro diagnostic product registration certificate applicable to the licensed field.\\\"}], \\\"sales_reporting_requirements\\\": [\\\"Submit sales reports and royalty calculation statements within 30 days after the end of each quarter\\\", \\\"Sales reports shall list net sales by product model and sales scenario\\\", \\\"Party B shall retain sales and settlement books and records for at least 7 years\\\"]}\", \"evidence_clauses\": \"[{\\\"clause_reference\\\": \\\"Article 6.1\\\", \\\"excerpt\\\": \\\"The portion of annual net sales not exceeding RMB 100,000,000 is calculated at 3%; the portion exceeding RMB 100,000,000 but not exceeding RMB 300,000,000 is calculated at 5%; the portion exceeding RMB 300,000,000 is calculated at 7%.\\\", \\\"evidence_explanation\\\": \\\"This clause directly specifies the royalty base, three sales tiers, and corresponding rates, and constitutes a progressive tiered calculation rule.\\\"}, {\\\"clause_reference\\\": \\\"Article 6.1, final paragraph, and Article 9\\\", \\\"excerpt\\\": \\\"Free research samples and validation samples provided to regulatory authorities in accordance with law are not included in net sales; Party B shall submit sales reports and royalty calculation statements within 30 days after the end of each quarter.\\\", \\\"evidence_explanation\\\": \\\"This part clarifies the exclusions from net sales and the reporting and settlement deadlines for sales royalties.\\\"}]\", \"answer_confidence\": \"0.99\", \"question_category\": \"Sales Royalty or License Fee\", \"patent_and_data_rights\": \"{\\\"patent_maintenance_party\\\": \\\"Party A is responsible for basic patents and patents related to core sequences; Party B is responsible for filing patents for independently developed improvements.\\\", \\\"patent_cost_allocation\\\": \\\"Annual fees for basic patents in the licensed territory shall be borne 50% by each party; costs for improvement technology patents shall be borne by the party applying for the rights.\\\", \\\"data_use_rights\\\": [\\\"Party B may use validation data, clinical evaluation data, and registration materials for registration submissions\\\", \\\"Party B may use necessary data for quality management, market access, and sales compliance\\\", \\\"Party A may access de-identified data for technical improvement and patent maintenance\\\"], \\\"commercialization_rights\\\": [\\\"Party B has sales rights in hospital and third-party independent medical laboratory scenarios\\\", \\\"Party B may entrust qualified manufacturers to produce the kit\\\", \\\"Party B has import and distribution rights in the licensed territory\\\"], \\\"sublicensing_rights\\\": \\\"Without Party A's written consent, Party B may not grant sublicenses to competitive in vitro diagnostic companies; limited technology use rights granted to non-competitive service providers shall be subject to confidentiality and purpose restrictions.\\\"}\", \"development_and_registration_responsibilities\": \"{\\\"licensor_responsibilities\\\": [\\\"Provide a list of candidate pathogens, primer and probe sequences\\\", \\\"Provide performance validation reports and reference material preparation methods\\\", \\\"Provide supporting analysis software interface documentation\\\", \\\"Responsible for filing and maintaining basic patents and patents related to core sequences\\\"], \\\"licensee_responsibilities\\\": [\\\"Responsible for product finalization and analytical performance validation\\\", \\\"Responsible for clinical evaluation\\\", \\\"Responsible for quality system construction\\\", \\\"Responsible for manufacturing filing or registration submission\\\", \\\"Bear commercialization costs\\\", \\\"Submit sales reports and royalty calculation statements\\\"], \\\"shared_responsibilities\\\": [\\\"Jointly cooperate with technical inquiries during registration review\\\", \\\"Jointly maintain data quality and compliance of the licensed product\\\"], \\\"milestones\\\": [{\\\"milestone_name\\\": \\\"Complete analytical performance validation\\\", \\\"milestone_type\\\": \\\"Product validation\\\", \\\"responsible_party\\\": \\\"Party B, Qiheng In Vitro Diagnostics Co., Ltd.\\\", \\\"target_date\\\": \\\"Within 9 months from the effective date of the contract\\\", \\\"completion_condition\\\": \\\"Complete validation of the limit of detection, precision, specificity, and anti-interference performance for the pathogen items specified in the contract and form a validation report.\\\"}, {\\\"milestone_name\\\": \\\"Submit product registration application\\\", \\\"milestone_type\\\": \\\"Regulatory submission\\\", \\\"responsible_party\\\": \\\"Party B, Qiheng In Vitro Diagnostics Co., Ltd.\\\", \\\"target_date\\\": \\\"Within 18 months from the effective date of the contract\\\", \\\"completion_condition\\\": \\\"Submit complete registration application materials to the competent drug regulatory authority and obtain an acceptance receipt.\\\"}, {\\\"milestone_name\\\": \\\"Obtain in vitro diagnostic product registration certificate\\\", \\\"milestone_type\\\": \\\"Marketing approval\\\", \\\"responsible_party\\\": \\\"Party B, Qiheng In Vitro Diagnostics Co., Ltd., with Party A providing technical cooperation\\\", \\\"target_date\\\": \\\"Within 30 months from the effective date of the contract\\\", \\\"completion_condition\\\": \\\"Obtain the applicable in vitro diagnostic product registration certificate covering the licensed field.\\\"}]}\"}","Sales royalties are calculated based on annual net sales of the product and use progressive tiered rates: the portion of annual net sales not exceeding RMB 100,000,000 is calculated at 3%; the portion exceeding RMB 100,000,000 but not exceeding RMB 300,000,000 is calculated at 5%; the portion exceeding RMB 300,000,000 is calculated at 7%. Free research samples and validation samples provided to regulatory authorities in accordance with law are not included in net sales. Party B shall submit sales reports and royalty calculation statements within 30 days after the end of each quarter.","How are sales royalties for the multiplex respiratory pathogen PCR detection kit calculated? What rates apply to the different annual net sales tiers?","Party A is Minglan Diagnostic Technology Research Institute, and Party B is Qiheng In Vitro Diagnostics Co., Ltd. Article 1: Party A licenses to Party B the multiplex respiratory pathogen PCR detection kit and its primer design, probe combination, and supporting analysis software technology. The licensed territory is mainland China, and the licensed field is limited to in vitro detection of respiratory pathogens in public hospitals, private hospitals, and third-party independent medical laboratories. Party B enjoys a partially exclusive license in hospital and independent medical laboratory scenarios, but Party A retains the right for internal research and non-commercial validation by scientific research institutions. Article 2: Party B obtains the right to research and develop, register, contract manufacture, sell, import, and distribute the kit within the licensed field. Without Party A's written consent, Party B may not sublicense to competitive in vitro diagnostic companies. Article 3: Party A shall provide a list of candidate pathogens, primer and probe sequences, performance validation reports, reference material preparation methods, and software interface documentation. Party B is responsible for product finalization, analytical performance validation, clinical evaluation, quality system construction, manufacturing filing or registration submission, and commercialization costs. Article 4: Party B shall complete analytical performance validation within 9 months from the effective date, submit registration application within 18 months, and obtain the applicable in vitro diagnostic product registration certificate within 30 months. Article 5: After obtaining the registration certificate, Party B shall pay Party A a registration milestone payment of RMB 800,000. Article 6.1: Party B shall pay sales royalties based on annual net sales of the product: for the portion of annual net sales not exceeding RMB 100,000,000, 3%; for the portion exceeding RMB 100,000,000 but not exceeding RMB 300,000,000, 5%; for the portion exceeding RMB 300,000,000, 7%. Free research samples and validation samples provided to regulatory authorities in accordance with law shall not be included in net sales. Article 7: Party A is responsible for filing and maintaining the basic patents and patents related to core sequences, and Party B is responsible for filing patents for independently developed improvements; the annual fees for the basic patents in the licensed territory shall be shared 50% by each party. Article 8: Party B may use validation data, clinical evaluation data, and registration materials for product registration, quality management, market access, and sales compliance, and Party A may access de-identified data for technical improvement and patent maintenance. Article 9: Party B shall submit sales reports and royalty calculation statements within 30 days after the end of each quarter, and shall retain relevant books and records for at least 7 years.","{\"indications_or_fields\": [\"In vitro detection of respiratory pathogens in hospitals\", \"In vitro detection of respiratory pathogens in third-party independent medical laboratories\"], \"territory\": \"Mainland China\", \"exclusivity\": \"Partially exclusive license\", \"licensed_rights\": [\"Research and development\", \"Analytical performance validation\", \"Registration submissions\", \"Contract manufacturing\", \"Sales\", \"Import\", \"Distribution\"]}","{\"royalty_terms\": [{\"rate\": 3, \"rate_unit\": \"percent\", \"royalty_base\": \"annual net sales of the product\", \"tier_condition\": \"The portion of annual net sales not exceeding RMB 100,000,000.\"}, {\"rate\": 5, \"rate_unit\": \"percent\", \"royalty_base\": \"annual net sales of the product\", \"tier_condition\": \"The portion of annual net sales exceeding RMB 100,000,000 but not exceeding RMB 300,000,000.\"}, {\"rate\": 7, \"rate_unit\": \"percent\", \"royalty_base\": \"annual net sales of the product\", \"tier_condition\": \"The portion of annual net sales exceeding RMB 300,000,000.\"}], \"milestone_payments\": [{\"amount\": 800000, \"currency\": \"RMB\", \"triggering_event\": \"Party B obtains the in vitro diagnostic product registration certificate applicable to the licensed field.\"}], \"sales_reporting_requirements\": [\"Submit sales reports and royalty calculation statements within 30 days after the end of each quarter\", \"Sales reports shall list net sales by product model and sales scenario\", \"Party B shall retain sales and settlement books and records for at least 7 years\"]}","[{\"clause_reference\": \"Article 6.1\", \"excerpt\": \"The portion of annual net sales not exceeding RMB 100,000,000 is calculated at 3%; the portion exceeding RMB 100,000,000 but not exceeding RMB 300,000,000 is calculated at 5%; the portion exceeding RMB 300,000,000 is calculated at 7%.\", \"evidence_explanation\": \"This clause directly specifies the royalty base, three sales tiers, and corresponding rates, and constitutes a progressive tiered calculation rule.\"}, {\"clause_reference\": \"Article 6.1, final paragraph, and Article 9\", \"excerpt\": \"Free research samples and validation samples provided to regulatory authorities in accordance with law are not included in net sales; Party B shall submit sales reports and royalty calculation statements within 30 days after the end of each quarter.\", \"evidence_explanation\": \"This part clarifies the exclusions from net sales and the reporting and settlement deadlines for sales royalties.\"}]","0.99","Sales Royalty or License Fee","{\"patent_maintenance_party\": \"Party A is responsible for basic patents and patents related to core sequences; Party B is responsible for filing patents for independently developed improvements.\", \"patent_cost_allocation\": \"Annual fees for basic patents in the licensed territory shall be borne 50% by each party; costs for improvement technology patents shall be borne by the party applying for the rights.\", \"data_use_rights\": [\"Party B may use validation data, clinical evaluation data, and registration materials for registration submissions\", \"Party B may use necessary data for quality management, market access, and sales compliance\", \"Party A may access de-identified data for technical improvement and patent maintenance\"], \"commercialization_rights\": [\"Party B has sales rights in hospital and third-party independent medical laboratory scenarios\", \"Party B may entrust qualified manufacturers to produce the kit\", \"Party B has import and distribution rights in the licensed territory\"], \"sublicensing_rights\": \"Without Party A's written consent, Party B may not grant sublicenses to competitive in vitro diagnostic companies; limited technology use rights granted to non-competitive service providers shall be subject to confidentiality and purpose restrictions.\"}","{\"licensor_responsibilities\": [\"Provide a list of candidate pathogens, primer and probe sequences\", \"Provide performance validation reports and reference material preparation methods\", \"Provide supporting analysis software interface documentation\", \"Responsible for filing and maintaining basic patents and patents related to core sequences\"], \"licensee_responsibilities\": [\"Responsible for product finalization and analytical performance validation\", \"Responsible for clinical evaluation\", \"Responsible for quality system construction\", \"Responsible for manufacturing filing or registration submission\", \"Bear commercialization costs\", \"Submit sales reports and royalty calculation statements\"], \"shared_responsibilities\": [\"Jointly cooperate with technical inquiries during registration review\", \"Jointly maintain data quality and compliance of the licensed product\"], \"milestones\": [{\"milestone_name\": \"Complete analytical performance validation\", \"milestone_type\": \"Product validation\", \"responsible_party\": \"Party B, Qiheng In Vitro Diagnostics Co., Ltd.\", \"target_date\": \"Within 9 months from the effective date of the contract\", \"completion_condition\": \"Complete validation of the limit of detection, precision, specificity, and anti-interference performance for the pathogen items specified in the contract and form a validation report.\"}, {\"milestone_name\": \"Submit product registration application\", \"milestone_type\": \"Regulatory submission\", \"responsible_party\": \"Party B, Qiheng In Vitro Diagnostics Co., Ltd.\", \"target_date\": \"Within 18 months from the effective date of the contract\", \"completion_condition\": \"Submit complete registration application materials to the competent drug regulatory authority and obtain an acceptance receipt.\"}, {\"milestone_name\": \"Obtain in vitro diagnostic product registration certificate\", \"milestone_type\": \"Marketing approval\", \"responsible_party\": \"Party B, Qiheng In Vitro Diagnostics Co., Ltd., with Party A providing technical cooperation\", \"target_date\": \"Within 30 months from the effective date of the contract\", \"completion_condition\": \"Obtain the applicable in vitro diagnostic product registration certificate covering the licensed field.\"}]}",{"id":693,"relate_table":661,"relate_id":694,"file_size":572,"file_name":695,"path":8,"duration":572,"cate":483,"file_format":664,"audio_rate":8,"audio_channel":522,"audio_bit_depth":522,"quality":8,"annotation":696,"cate_name":666,"answer":697,"question":698,"contract_text":699,"license_scope":700,"commercial_terms":701,"evidence_clauses":702,"answer_confidence":703,"question_category":704,"patent_and_data_rights":705,"development_and_registration_responsibilities":706},15220,285261512,"样例_1.json","{\"answer\": \"Party B, Chengming Pharmaceutical Development Co., Ltd., bears the primary registration responsibility for the licensed product in mainland China, including regulatory communications, submission of the marketing authorization application, payment of registration fees, and obtaining marketing authorization. Party B shall also submit the marketing authorization application within 30 months from the effective date of the contract and strive to obtain marketing authorization within 48 months. Party A, Lanyue Biotechnology Co., Ltd., does not bear the lead filing responsibility, but must provide technical materials and cooperate in supplementing materials, explaining historical data, responding to regulatory inquiries, and attending necessary expert meetings; delays caused by Party A's failure to provide materials in a timely manner shall result in corresponding extensions of the relevant deadlines.\", \"question\": \"Under the contract, which party is responsible for the registration submission and obtaining marketing authorization for LY-201 in mainland China? Does Party A still bear cooperation obligations?\", \"contract_text\": \"Party A is Lanyue Biotechnology Co., Ltd., and Party B is Chengming Pharmaceutical Development Co., Ltd. Article 1.1: Party A grants Party B an exclusive license in mainland China (excluding Hong Kong SAR, Macao SAR, and Taiwan) to develop, register, manufacture, use, import, sell, and distribute the LY-201 antibody-drug conjugate for HER2-low metastatic breast cancer and HER2-low gastric cancer. Article 1.2: Party B may grant sublicenses with Party A's prior written consent and provided that the sublicensee assumes equivalent compliance obligations. Article 2.1: Party A shall provide Party B with cell lines, analytical methods, pharmaceutical research materials, existing nonclinical data, and process transfer documents within 60 days after the contract takes effect, and shall provide reasonable technical consultation during research and development. Article 3.1: Party B is responsible for all nonclinical studies, clinical trials, trial costs, CRO management, manufacturing preparation, regulatory communications, and registration submissions for the licensed product in the licensed territory. Article 3.2: Party A shall cooperate with Party B in supplementing technical materials, explaining historical data, responding to regulatory inquiries, and attending necessary expert meetings. Article 4.1: Party B shall complete enrollment of the first subject in the Phase III clinical trial within 12 months from the effective date of the contract, submit a marketing authorization application to the National Medical Products Administration within 30 months, and obtain marketing authorization within 48 months; delays caused by Party A's failure to provide materials in a timely manner shall be correspondingly extended. Article 5.1: Party B shall pay Party A a registration milestone payment of RMB 3,000,000 upon obtaining marketing authorization. Article 5.2: For the portion of annual net sales not exceeding RMB 500,000,000, a 4% sales royalty shall be paid; for the portion exceeding that amount, a 6% sales royalty shall be paid. Article 6.1: Party A is responsible for the filing, maintenance, annuity payment, and infringement enforcement decisions for the basic patents in the licensed territory; Party B shall provide commercialization information and bear the actual costs incurred by Party A for maintaining the basic patents. Article 7.1: Party B may use clinical data, pharmaceutical data, and registration materials within the licensed field for research, submissions, review communications, and commercialization; Party A has the right to access de-identified data for patent maintenance, compliance audits, and basic research outside the licensed field. Article 8.1: Party B is responsible for manufacturing, promotion, sales, distribution, and pharmacovigilance after product launch. Article 9.1: Party B shall submit sales reports quarterly and complete royalty settlement within 45 days after the end of each quarter.\", \"license_scope\": \"{\\\"indications_or_fields\\\": [\\\"HER2-low metastatic breast cancer treatment\\\", \\\"HER2-low gastric cancer treatment\\\"], \\\"territory\\\": \\\"Mainland China, excluding Hong Kong SAR, Macao SAR, and Taiwan\\\", \\\"exclusivity\\\": \\\"Exclusive license\\\", \\\"licensed_rights\\\": [\\\"Research and development\\\", \\\"Clinical trials\\\", \\\"Registration submissions\\\", \\\"Manufacturing\\\", \\\"Use\\\", \\\"Import\\\", \\\"Sales\\\", \\\"Distribution\\\", \\\"Sublicensing with consent\\\"]}\", \"commercial_terms\": \"{\\\"royalty_terms\\\": [{\\\"rate\\\": 4, \\\"rate_unit\\\": \\\"percent\\\", \\\"royalty_base\\\": \\\"annual net sales of the product\\\", \\\"tier_condition\\\": \\\"The portion of annual net sales not exceeding RMB 500,000,000.\\\"}, {\\\"rate\\\": 6, \\\"rate_unit\\\": \\\"percent\\\", \\\"royalty_base\\\": \\\"annual net sales of the product\\\", \\\"tier_condition\\\": \\\"The portion of annual net sales exceeding RMB 500,000,000.\\\"}], \\\"milestone_payments\\\": [{\\\"amount\\\": 3000000, \\\"currency\\\": \\\"RMB\\\", \\\"triggering_event\\\": \\\"Party B obtains marketing authorization for LY-201 in the licensed field and licensed territory.\\\"}], \\\"sales_reporting_requirements\\\": [\\\"Party B shall submit sales reports quarterly\\\", \\\"Complete sales royalty settlement within 45 days after the end of each quarter\\\", \\\"Sales reports shall state net sales by product, indication, and region\\\"]}\", \"evidence_clauses\": \"[{\\\"clause_reference\\\": \\\"Articles 3.1 and 4.1\\\", \\\"excerpt\\\": \\\"Party B is responsible for all nonclinical studies, clinical trials, trial costs, CRO management, manufacturing preparation, regulatory communications, and registration submissions for the licensed product in the licensed territory; Party B shall submit a marketing authorization application to the National Medical Products Administration within 30 months from the effective date of the contract and obtain marketing authorization within 48 months.\\\", \\\"evidence_explanation\\\": \\\"This clause expressly allocates the primary obligations for registration submissions, related costs, and obtaining marketing authorization to Party B, and sets timelines for submission and approval.\\\"}, {\\\"clause_reference\\\": \\\"Article 3.2\\\", \\\"excerpt\\\": \\\"Party A shall cooperate with Party B in supplementing technical materials, explaining historical data, responding to regulatory inquiries, and attending necessary expert meetings.\\\", \\\"evidence_explanation\\\": \\\"This clause indicates that Party A bears registration cooperation and data support obligations, but does not transfer the lead registration submission responsibility to Party A.\\\"}]\", \"answer_confidence\": \"0.98\", \"question_category\": \"Registration Responsibility\", \"patent_and_data_rights\": \"{\\\"patent_maintenance_party\\\": \\\"Party A is responsible for the filing, maintenance, annuity payment, and infringement enforcement decisions for the basic patents in the licensed territory.\\\", \\\"patent_cost_allocation\\\": \\\"Party B bears the actual costs incurred by Party A for maintaining the basic patents.\\\", \\\"data_use_rights\\\": [\\\"Party B may use clinical data, pharmaceutical data, and registration materials within the licensed field for research and registration submissions\\\", \\\"Party B may provide data necessary for contract performance to regulatory authorities, CROs, and approved sublicensees\\\", \\\"Party A may access de-identified data for patent maintenance, compliance audits, and basic research outside the licensed field\\\"], \\\"commercialization_rights\\\": [\\\"Party B is responsible for manufacturing preparation\\\", \\\"Party B has the right to promote, sell, and distribute in the licensed territory\\\", \\\"Party B has the right to import the product\\\"], \\\"sublicensing_rights\\\": \\\"Party B may grant sublicenses with Party A's prior written consent and provided that the sublicensee assumes equivalent confidentiality, compliance, and payment obligations.\\\"}\", \"development_and_registration_responsibilities\": \"{\\\"licensor_responsibilities\\\": [\\\"Provide cell lines, analytical methods, pharmaceutical research materials, existing nonclinical data, and process transfer documents\\\", \\\"Provide reasonable technical consultation during research and development\\\", \\\"Cooperate in supplementing technical materials, explaining historical data, and responding to regulatory inquiries\\\", \\\"Attend necessary regulatory expert meetings\\\"], \\\"licensee_responsibilities\\\": [\\\"Responsible for nonclinical studies and clinical trials\\\", \\\"Responsible for CRO management and all research and development costs\\\", \\\"Responsible for manufacturing preparation\\\", \\\"Responsible for regulatory communications and marketing authorization application\\\", \\\"Responsible for obtaining marketing authorization and bearing registration fees\\\", \\\"Responsible for post-marketing pharmacovigilance\\\"], \\\"shared_responsibilities\\\": [\\\"Jointly cooperate with regulatory authorities' supplementary information requests\\\", \\\"Jointly ensure clinical and registration materials comply with applicable laws and regulations\\\"], \\\"milestones\\\": [{\\\"milestone_name\\\": \\\"First subject enrolled in Phase III clinical trial\\\", \\\"milestone_type\\\": \\\"Clinical trial\\\", \\\"responsible_party\\\": \\\"Party B, Chengming Pharmaceutical Development Co., Ltd.\\\", \\\"target_date\\\": \\\"Within 12 months from the effective date of the contract\\\", \\\"completion_condition\\\": \\\"Complete enrollment of the first subject as specified in the Phase III clinical trial protocol and form verifiable trial records.\\\"}, {\\\"milestone_name\\\": \\\"Submit marketing authorization application\\\", \\\"milestone_type\\\": \\\"Regulatory submission\\\", \\\"responsible_party\\\": \\\"Party B, Chengming Pharmaceutical Development Co., Ltd.\\\", \\\"target_date\\\": \\\"Within 30 months from the effective date of the contract\\\", \\\"completion_condition\\\": \\\"Formally submit the LY-201 marketing authorization application to the National Medical Products Administration and obtain an acceptance receipt.\\\"}, {\\\"milestone_name\\\": \\\"Obtain marketing authorization\\\", \\\"milestone_type\\\": \\\"Marketing approval\\\", \\\"responsible_party\\\": \\\"Party B, Chengming Pharmaceutical Development Co., Ltd., with Party A providing cooperation\\\", \\\"target_date\\\": \\\"Within 48 months from the effective date of the contract, excluding any period of delay caused by Party A in providing materials\\\", \\\"completion_condition\\\": \\\"Obtain marketing authorization applicable to the licensed field and licensed territory.\\\"}]}\"}","Party B, Chengming Pharmaceutical Development Co., Ltd., bears the primary registration responsibility for the licensed product in mainland China, including regulatory communications, submission of the marketing authorization application, payment of registration fees, and obtaining marketing authorization. Party B shall also submit the marketing authorization application within 30 months from the effective date of the contract and strive to obtain marketing authorization within 48 months. Party A, Lanyue Biotechnology Co., Ltd., does not bear the lead filing responsibility, but must provide technical materials and cooperate in supplementing materials, explaining historical data, responding to regulatory inquiries, and attending necessary expert meetings; delays caused by Party A's failure to provide materials in a timely manner shall result in corresponding extensions of the relevant deadlines.","Under the contract, which party is responsible for the registration submission and obtaining marketing authorization for LY-201 in mainland China? Does Party A still bear cooperation obligations?","Party A is Lanyue Biotechnology Co., Ltd., and Party B is Chengming Pharmaceutical Development Co., Ltd. Article 1.1: Party A grants Party B an exclusive license in mainland China (excluding Hong Kong SAR, Macao SAR, and Taiwan) to develop, register, manufacture, use, import, sell, and distribute the LY-201 antibody-drug conjugate for HER2-low metastatic breast cancer and HER2-low gastric cancer. Article 1.2: Party B may grant sublicenses with Party A's prior written consent and provided that the sublicensee assumes equivalent compliance obligations. Article 2.1: Party A shall provide Party B with cell lines, analytical methods, pharmaceutical research materials, existing nonclinical data, and process transfer documents within 60 days after the contract takes effect, and shall provide reasonable technical consultation during research and development. Article 3.1: Party B is responsible for all nonclinical studies, clinical trials, trial costs, CRO management, manufacturing preparation, regulatory communications, and registration submissions for the licensed product in the licensed territory. Article 3.2: Party A shall cooperate with Party B in supplementing technical materials, explaining historical data, responding to regulatory inquiries, and attending necessary expert meetings. Article 4.1: Party B shall complete enrollment of the first subject in the Phase III clinical trial within 12 months from the effective date of the contract, submit a marketing authorization application to the National Medical Products Administration within 30 months, and obtain marketing authorization within 48 months; delays caused by Party A's failure to provide materials in a timely manner shall be correspondingly extended. Article 5.1: Party B shall pay Party A a registration milestone payment of RMB 3,000,000 upon obtaining marketing authorization. Article 5.2: For the portion of annual net sales not exceeding RMB 500,000,000, a 4% sales royalty shall be paid; for the portion exceeding that amount, a 6% sales royalty shall be paid. Article 6.1: Party A is responsible for the filing, maintenance, annuity payment, and infringement enforcement decisions for the basic patents in the licensed territory; Party B shall provide commercialization information and bear the actual costs incurred by Party A for maintaining the basic patents. Article 7.1: Party B may use clinical data, pharmaceutical data, and registration materials within the licensed field for research, submissions, review communications, and commercialization; Party A has the right to access de-identified data for patent maintenance, compliance audits, and basic research outside the licensed field. Article 8.1: Party B is responsible for manufacturing, promotion, sales, distribution, and pharmacovigilance after product launch. Article 9.1: Party B shall submit sales reports quarterly and complete royalty settlement within 45 days after the end of each quarter.","{\"indications_or_fields\": [\"HER2-low metastatic breast cancer treatment\", \"HER2-low gastric cancer treatment\"], \"territory\": \"Mainland China, excluding Hong Kong SAR, Macao SAR, and Taiwan\", \"exclusivity\": \"Exclusive license\", \"licensed_rights\": [\"Research and development\", \"Clinical trials\", \"Registration submissions\", \"Manufacturing\", \"Use\", \"Import\", \"Sales\", \"Distribution\", \"Sublicensing with consent\"]}","{\"royalty_terms\": [{\"rate\": 4, \"rate_unit\": \"percent\", \"royalty_base\": \"annual net sales of the product\", \"tier_condition\": \"The portion of annual net sales not exceeding RMB 500,000,000.\"}, {\"rate\": 6, \"rate_unit\": \"percent\", \"royalty_base\": \"annual net sales of the product\", \"tier_condition\": \"The portion of annual net sales exceeding RMB 500,000,000.\"}], \"milestone_payments\": [{\"amount\": 3000000, \"currency\": \"RMB\", \"triggering_event\": \"Party B obtains marketing authorization for LY-201 in the licensed field and licensed territory.\"}], \"sales_reporting_requirements\": [\"Party B shall submit sales reports quarterly\", \"Complete sales royalty settlement within 45 days after the end of each quarter\", \"Sales reports shall state net sales by product, indication, and region\"]}","[{\"clause_reference\": \"Articles 3.1 and 4.1\", \"excerpt\": \"Party B is responsible for all nonclinical studies, clinical trials, trial costs, CRO management, manufacturing preparation, regulatory communications, and registration submissions for the licensed product in the licensed territory; Party B shall submit a marketing authorization application to the National Medical Products Administration within 30 months from the effective date of the contract and obtain marketing authorization within 48 months.\", \"evidence_explanation\": \"This clause expressly allocates the primary obligations for registration submissions, related costs, and obtaining marketing authorization to Party B, and sets timelines for submission and approval.\"}, {\"clause_reference\": \"Article 3.2\", \"excerpt\": \"Party A shall cooperate with Party B in supplementing technical materials, explaining historical data, responding to regulatory inquiries, and attending necessary expert meetings.\", \"evidence_explanation\": \"This clause indicates that Party A bears registration cooperation and data support obligations, but does not transfer the lead registration submission responsibility to Party A.\"}]","0.98","Registration Responsibility","{\"patent_maintenance_party\": \"Party A is responsible for the filing, maintenance, annuity payment, and infringement enforcement decisions for the basic patents in the licensed territory.\", \"patent_cost_allocation\": \"Party B bears the actual costs incurred by Party A for maintaining the basic patents.\", \"data_use_rights\": [\"Party B may use clinical data, pharmaceutical data, and registration materials within the licensed field for research and registration submissions\", \"Party B may provide data necessary for contract performance to regulatory authorities, CROs, and approved sublicensees\", \"Party A may access de-identified data for patent maintenance, compliance audits, and basic research outside the licensed field\"], \"commercialization_rights\": [\"Party B is responsible for manufacturing preparation\", \"Party B has the right to promote, sell, and distribute in the licensed territory\", \"Party B has the right to import the product\"], \"sublicensing_rights\": \"Party B may grant sublicenses with Party A's prior written consent and provided that the sublicensee assumes equivalent confidentiality, compliance, and payment obligations.\"}","{\"licensor_responsibilities\": [\"Provide cell lines, analytical methods, pharmaceutical research materials, existing nonclinical data, and process transfer documents\", \"Provide reasonable technical consultation during research and development\", \"Cooperate in supplementing technical materials, explaining historical data, and responding to regulatory inquiries\", \"Attend necessary regulatory expert meetings\"], \"licensee_responsibilities\": [\"Responsible for nonclinical studies and clinical trials\", \"Responsible for CRO management and all research and development costs\", \"Responsible for manufacturing preparation\", \"Responsible for regulatory communications and marketing authorization application\", \"Responsible for obtaining marketing authorization and bearing registration fees\", \"Responsible for post-marketing pharmacovigilance\"], \"shared_responsibilities\": [\"Jointly cooperate with regulatory authorities' supplementary information requests\", \"Jointly ensure clinical and registration materials comply with applicable laws and regulations\"], \"milestones\": [{\"milestone_name\": \"First subject enrolled in Phase III clinical trial\", \"milestone_type\": \"Clinical trial\", \"responsible_party\": \"Party B, Chengming Pharmaceutical Development Co., Ltd.\", \"target_date\": \"Within 12 months from the effective date of the contract\", \"completion_condition\": \"Complete enrollment of the first subject as specified in the Phase III clinical trial protocol and form verifiable trial records.\"}, {\"milestone_name\": \"Submit marketing authorization application\", \"milestone_type\": \"Regulatory submission\", \"responsible_party\": \"Party B, Chengming Pharmaceutical Development Co., Ltd.\", \"target_date\": \"Within 30 months from the effective date of the contract\", \"completion_condition\": \"Formally submit the LY-201 marketing authorization application to the National Medical Products Administration and obtain an acceptance receipt.\"}, {\"milestone_name\": \"Obtain marketing authorization\", \"milestone_type\": \"Marketing approval\", \"responsible_party\": \"Party B, Chengming Pharmaceutical Development Co., Ltd., with Party A providing cooperation\", \"target_date\": \"Within 48 months from the effective date of the contract, excluding any period of delay caused by Party A in providing materials\", \"completion_condition\": \"Obtain marketing authorization applicable to the licensed field and licensed territory.\"}]}","{\"answer\":\"Within the licensed field, Party B may use, copy, and analyze clinical data, pharmacological and toxicological data, process data, and registration materials, and may submit data necessary for contract performance to regulatory authorities, or provide it to CROs, regulatory consultants, and Party A-approved sublicensees bound by confidentiality obligations. Original data records shall be kept by the party that generates them. Party A may access de-identified data generated by Party B for platform safety evaluation, patent maintenance, and basic research outside the licensed field, but may not provide identifiable personal information to any third party, nor use Party B's confidential clinical data to develop competitive products within the licensed field.\",\"question\":\"Regarding the clinical and R&D data generated by the ZX-7 project, how may Party B use or provide it to third parties? What access and use rights does Party A have?\",\"contract_text\":\"Party A is Yaochen Gene Technology Co., Ltd., and Party B is Yuanchuan Biopharmaceutical Co., Ltd. Article 1: Party A grants Party B an exclusive license worldwide to research and develop, clinically develop, register, manufacture, import, promote, sell, and distribute products using the ZX-7 base editing delivery platform and its improvements for hereditary retinal diseases. The licensed field includes Leber congenital amaurosis, retinitis pigmentosa, and other hereditary retinal diseases listed in the contract annex. Article 2: Party B may disclose technology and data necessary for contract performance to CROs, CMOs, regulatory consultants, and Party A-approved commercial partners bound by confidentiality obligations, and may grant sublicenses after obtaining Party A's written consent. Article 3: Party A shall deliver the platform technology package, vector construction plans, existing in vitro and animal study data, analytical methods, and patent documents, and shall provide technical consultation on Party B's preclinical plans. Article 4: Party B is responsible for preclinical studies, clinical trials, subject protection, regulatory submissions, manufacturing process development, commercialization, and related costs. Both parties are jointly responsible for developing the data management plan, sample coding rules, and serious adverse event reporting procedures. Article 5: Party B shall complete the clinical trial application for the first candidate product within 15 months from the effective date, complete first subject dosing within 36 months, and submit the marketing authorization application for the first indication within 60 months. Article 6: Party B shall pay a milestone payment of USD 2,000,000 when the first indication obtains marketing authorization; after product launch, Party B shall pay a 5% sales royalty on global net sales. Article 7: Party A is responsible for filing, maintaining, and litigation strategy for the platform basic patents, and Party B bears 70% of global basic patent costs; product patents independently developed by Party B are Party B's responsibility, and Party A enjoys a royalty-free right to use them within the licensed field. Article 8.1: Original records of clinical data, pharmacological and toxicological data, process data, and registration materials shall be kept by the party that generates them, and Party B has the right within the licensed field to use, copy, analyze, submit to regulatory authorities, and provide such data to approved sublicensees. Article 8.2: Party A may access de-identified data generated by Party B for platform safety evaluation, patent maintenance, and basic research outside the licensed field, but may not provide identifiable personal information to any third party, nor use Party B's confidential clinical data to develop competitive products within the licensed field. Article 9: Party B is responsible for global commercialization, supply chain, marketing, sales, and pharmacovigilance of the product, and shall report net sales to Party A quarterly.\",\"license_scope\":\"{\\\"indications_or_fields\\\": [\\\"Leber congenital amaurosis\\\", \\\"Retinitis pigmentosa\\\", \\\"Other hereditary retinal diseases listed in the contract annex\\\"], \\\"territory\\\": \\\"Worldwide\\\", \\\"exclusivity\\\": \\\"Exclusive license\\\", \\\"licensed_rights\\\": [\\\"Preclinical research and development\\\", \\\"Clinical development\\\", \\\"Regulatory submissions\\\", \\\"Manufacturing\\\", \\\"Import\\\", \\\"Promotion\\\", \\\"Sales\\\", \\\"Distribution\\\", \\\"Sublicensing after Party A's written consent\\\"]}\",\"commercial_terms\":\"{\\\"royalty_terms\\\": [{\\\"rate\\\": 5, \\\"rate_unit\\\": \\\"percent\\\", \\\"royalty_base\\\": \\\"global net sales of the product\\\", \\\"tier_condition\\\": \\\"Applies uniformly to global net sales after all licensed products are launched.\\\"}], \\\"milestone_payments\\\": [{\\\"amount\\\": 2000000, \\\"currency\\\": \\\"USD\\\", \\\"triggering_event\\\": \\\"The first licensed indication obtains marketing authorization.\\\"}], \\\"sales_reporting_requirements\\\": [\\\"Party B shall report global net sales to Party A quarterly\\\", \\\"Submit sales reports and pay accrued sales royalties within 45 days after the end of the quarter\\\", \\\"Sales reports shall distinguish by indication, country, and product specification\\\"]}\",\"evidence_clauses\":\"[{\\\"clause_reference\\\": \\\"Article 8.1\\\", \\\"excerpt\\\": \\\"Party B has the right within the licensed field to use, copy, analyze, submit to regulatory authorities, and provide clinical data, pharmacological and toxicological data, process data, and registration materials to approved sublicensees.\\\", \\\"evidence_explanation\\\": \\\"This clause clarifies Party B's scope of use of project data, right to make regulatory submissions, and authority to provide data to approved third parties, and limits use to the licensed field.\\\"}, {\\\"clause_reference\\\": \\\"Article 8.2\\\", \\\"excerpt\\\": \\\"Party A may access de-identified data generated by Party B for platform safety evaluation, patent maintenance, and basic research outside the licensed field, but may not provide identifiable personal information to any third party, nor use Party B's confidential clinical data to develop competitive products within the licensed field.\\\", \\\"evidence_explanation\\\": \\\"This clause sets out Party A's data access purposes and boundaries, including de-identification requirements, permitted uses, and restrictions on disclosing personal information and conducting competitive development.\\\"}, {\\\"clause_reference\\\": \\\"Article 2\\\", \\\"excerpt\\\": \\\"Party B may disclose technology and data necessary for contract performance to CROs, CMOs, regulatory consultants, and Party A-approved commercial partners bound by confidentiality obligations.\\\", \\\"evidence_explanation\\\": \\\"This clause supplements the scope of recipients and preconditions for Party B to provide data to external service providers, namely that it is necessary for contract performance, confidentiality obligations are assumed, and Party A's approval is obtained in sublicensing scenarios.\\\"}]\",\"answer_confidence\":\"0.97\",\"question_category\":\"Data Use Rights\",\"patent_and_data_rights\":\"{\\\"patent_maintenance_party\\\": \\\"Party A is responsible for filing, maintaining, and litigation strategy for platform basic patents; Party B is responsible for product patents it independently develops.\\\", \\\"patent_cost_allocation\\\": \\\"Party B bears 70% of global basic patent costs; costs for product patents independently developed by Party B shall be borne by Party B.\\\", \\\"data_use_rights\\\": [\\\"Party B may use, copy, and analyze clinical and R&D data within the licensed field\\\", \\\"Party B may submit data and registration materials to regulatory authorities\\\", \\\"Party B may provide data necessary for contract performance to CROs, regulatory consultants, and approved sublicensees bound by confidentiality obligations\\\", \\\"Party A may access de-identified data generated by Party B for platform safety evaluation, patent maintenance, and basic research outside the licensed field\\\", \\\"Party A may not disclose identifiable personal information or use Party B's confidential clinical data to develop competitive products within the licensed field\\\"], \\\"commercialization_rights\\\": [\\\"Party B has global product manufacturing rights\\\", \\\"Party B has global promotion, sales, and distribution rights\\\", \\\"Party B is responsible for the global supply chain and post-marketing pharmacovigilance\\\"], \\\"sublicensing_rights\\\": \\\"Party B may disclose data necessary for contract performance to service providers bound by confidentiality obligations; granting sublicenses to commercial partners requires prior written consent from Party A, and Party B must ensure that sublicensees assume data protection and reporting obligations no less stringent than those in this contract.\\\"}\",\"development_and_registration_responsibilities\":\"{\\\"licensor_responsibilities\\\": [\\\"Deliver the platform technology package, vector construction plans, and existing research data\\\", \\\"Provide analytical methods and patent documents\\\", \\\"Provide technical consultation on preclinical plans\\\", \\\"Responsible for filing, maintaining, and litigation strategy for platform basic patents\\\", \\\"Access de-identified data for platform safety evaluation and patent maintenance\\\"], \\\"licensee_responsibilities\\\": [\\\"Responsible for preclinical studies and clinical trials\\\", \\\"Responsible for subject protection and safety reporting\\\", \\\"Responsible for regulatory submissions\\\", \\\"Responsible for manufacturing process development\\\", \\\"Bear commercialization and related R&D costs\\\", \\\"Responsible for global product supply chain, promotion, sales, and pharmacovigilance\\\"], \\\"shared_responsibilities\\\": [\\\"Jointly develop the data management plan\\\", \\\"Jointly develop sample coding rules\\\", \\\"Jointly develop serious adverse event reporting procedures\\\", \\\"Jointly comply with applicable data protection and clinical trial regulations\\\"], \\\"milestones\\\": [{\\\"milestone_name\\\": \\\"Submit clinical trial application for first candidate product\\\", \\\"milestone_type\\\": \\\"Regulatory submission\\\", \\\"responsible_party\\\": \\\"Party B, Yuanchuan Biopharmaceutical Co., Ltd., with Party A providing technical materials and consultation\\\", \\\"target_date\\\": \\\"Within 15 months from the effective date of the contract\\\", \\\"completion_condition\\\": \\\"Complete integration of preclinical materials and submit a clinical trial application to the competent regulatory authority.\\\"}, {\\\"milestone_name\\\": \\\"First subject dosing\\\", \\\"milestone_type\\\": \\\"Clinical trial\\\", \\\"responsible_party\\\": \\\"Party B, Yuanchuan Biopharmaceutical Co., Ltd.\\\", \\\"target_date\\\": \\\"Within 36 months from the effective date of the contract\\\", \\\"completion_condition\\\": \\\"Complete first subject dosing under the approved clinical trial protocol and form traceable records.\\\"}, {\\\"milestone_name\\\": \\\"Submit marketing authorization application for first indication\\\", \\\"milestone_type\\\": \\\"Regulatory submission\\\", \\\"responsible_party\\\": \\\"Party B, Yuanchuan Biopharmaceutical Co., Ltd.\\\", \\\"target_date\\\": \\\"Within 60 months from the effective date of the contract\\\", \\\"completion_condition\\\": \\\"Submit a complete marketing authorization application for the first licensed indication to the applicable regulatory authority.\\\"}]}\"}","MOBIUSI INC","https:\u002F\u002Fstatic.mobiusi.com\u002Fmobiwusi\u002F20250829\u002F7bf4ac62b4533e2b809998a6f1c5491e.png?Expires=1792463130&OSSAccessKeyId=LTAI5tH8MQqhgeiAtrzCHrxM&Signature=v6Tr8jBrdm4s5wU1SnnyGsYg%2Bhw%3D&x-oss-process=image%2Fresize%2Cm_fill%2Cw_35%2Ch_35",[711,717],{"type":712,"title":713,"count_data":714},"bar","Length distribution",[715],{"name":716,"value":483},"1k lower",{"type":718,"title":719,"count_data":720},"pie","Language distribution",[721],{"name":722,"value":483},"English"]